Arteriocyte is now a part of Isto Biologics.

News + Views

Blog

Mitchell Seyedin, Ph.D., Joins ISTO Technologies, Inc. as President and Chief Executive Officer

Sep 4, 2003

St. Louis, Missouri, September 4, 2003–ISTO Technologies, Inc. today announced the appointment of Mitchell Seyedin, Ph.D., to succeed Joseph Feder, Ph.D., as President and Chief Executive Officer. Dr. Feder, who served in this position since co-founding Isto Technologies in 1997, will continue as Chairman. Dr. Seyedin brings more than 24 years experience in medical research, product development and building successful companies.

Most recently, Dr. Seyedin was co-founder, President and Chief Executive Officer of CBYON, a medical technology company that develops and markets advanced visualization and navigation systems for minimally-invasive surgery. Prior to that, Dr. Seyedin founded Orquest, Inc., a bone and cartilage tissue engineering company that was recently acquired by Johnson & Johnson. He served as President and Chief Executive Officer until 1996, and Chairman and Chief Scientific Officer until 1999. Earlier in his career, Dr. Seyedin co-founded Metra Biosystems, Inc., a diagnostic company that went public in 1995 and was acquired by Quidel (Nasdaq:QDEL) in 1999. He also served as Director of the Cellular Biochemistry Department at Collagen Corporation, where he was responsible for all aspects of tissue engineering and growth factor research programs and was awarded 11 patents.

Dr. Seyedin received an undergraduate degree in Chemistry from the University of Wisconsin, River Falls, and a Ph.D. in Biological Chemistry from the University of South Carolina, Columbia. He was also a Postdoctoral Research Fellow at the University of California, Berkeley.

“Dr. Seyedin will lead the Company through its next phase of growth and the commercialization of our proprietary cartilage and bone regeneration technology platforms. We are very pleased that an industry veteran with Dr. Seyedin’s credentials and background has joined the Isto team,” said Joseph Feder.

About ISTO Technologies
ISTO Technologies is an emerging biotechnology company that is developing advanced therapeutics for the repair, replacement and regeneration of musculoskeletal tissue to restore function for living. Isto Technologies has entered into a collaborative development alliance for its neocartilage allograft product with Zimmer, Inc. (NYSE:ZMH), a global leader in the design, development, manufacturing, and marketing of orthopaedic reconstructive implants and fracture management products. The Company is also developing novel bone repair solutions and an antiarthritis drug discovery platform.

For additional information visit ISTO Technologies’ website at www.istobiologics.com, or contact the Company by phone at (314) 995-6049, or by email at info@istotech.com.

To top